Mutation profile of Low grade Uterine Cancer of poor prognosis
Research type
Research Study
Full title
Mutation profile of Low grade endometrial endometrioid adenocarcinoma with poor prognosis
IRAS ID
217235
Contact name
Samar Elorbany
Contact email
Sponsor organisation
St George's University Hospital NHS foundation trust
Duration of Study in the UK
1 years, 6 months, days
Research summary
Currently, Endometrial cancer is classified pathologically to type I (Endometrioid histology) and type II (Serous and Clear cell histology). Clinically, there is substantial overlap between the 2 groups. 20% of type I cancers tend to recur and have worse prognosis whereas 50% of type II don’t recur. Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) trial classified endometrial cancer to 3 groups based on clinical and pathological criteria, low risk, intermediate risk and high risk. This classification helped to triage patients who need adjuvant treatment however we still find that 20 % of patients receive unnecessary radiotherapy and 10% develop distant recurrence in spite of being low risk by (PORTEC) criteria. Recent studies by The cancer genome atlas (TCGA) group classified endometrial cancer into 4 Clusters, with Cluster 4 including the pathological type II cancers. Their findings also suggested that there are subsets of endometrial cancer who have molecular profile different from their histopathological type and grade. However that classification was correlated with histopathology but was not correlated to the clinical outcomes of those patients, also it is too expensive and laborious to be brought to clinical practice. In this pilot study, we aim to explore particular molecular features that could be brought to clinical practice and could characterize patients with low grade endometrial cancer who will have worse outcome. The study would include patients with endometrial cancer who had treatment or diagnostic biopsy in St George’s University hospital. The initial set would include patients with low grade endometrial endometrioid carcinoma and the validation set would include patients with other types of uterine cancer for comparison. Mainly Archived anonymized tissue samples retrieved from pathology archives will be used. Fresh samples will only be used with patient consent. Genetic mutation analysis will be done on tumour samples and normal tissue for biomarker discovery
REC name
London - Stanmore Research Ethics Committee
REC reference
17/LO/1145
Date of REC Opinion
17 Aug 2017
REC opinion
Further Information Favourable Opinion